Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.44 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15046453 | 0.91 | ALDH1A3 (0.49) | ALDH1A3SRCMAPTTP53STIM1 | |
| SCHEMBL15033999 | 0.88 | ALDH1A3 (0.47) | ALDH1A3MAPTTP53RAB9AGAA | |
| SCHEMBL15033980 | 0.87 | MAPT (0.52) | PTGDR2MAPTMAPK1RAB9AALDH1A1 | |
| SCHEMBL15033978 | 0.81 | GABRA2 (0.43) | PTGDR2MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL15034556 | 0.81 | SMN1; SMN2 (0.51) | MAPTTP53MAPK1RAB9AALDH1A1 | |
| SCHEMBL15019885 | 0.80 | GABRA2 (0.42) | PTGDR2MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL15034557 | 0.80 | POLB (0.46) | MAPTTP53MAPK1RAB9AALDH1A1 | |
| SCHEMBL15034555 | 0.80 | GRM5 (0.54) | MAPTTP53MAPK1RAB9AALDH1A1 | |
| SCHEMBL15033935 | 0.79 | GRM5 (0.43) | SRCPTGDR2MAPTALDH1A1PTGS2 | |
| SCHEMBL15034559 | 0.79 | HPGD (0.52) | MAPTTP53MAPK1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791118-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLU5 RECEPTORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-16 | — | — | EP | disclosed |
| EP-2791117-B1 | 4-ARYL IMIDAZOLE DERIVATIVES AS MGLU5 POSITIVE ALLESTERIC MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8716277-B2 | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-8716277-B2 | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-20130158011-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158011-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| WO-2013087807-A1 | 4-ARYL IMIDAZOLE DERIVATIVES AS MGLU5 POSITIVE ALLESTERIC MODIULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158011-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | ALDH1A3 3638/4885SRC 4087/4885PTGDR2 291/4885 |
| US-20130158038-A1 | NOVEL COMPOUNDS | GRM5, GRIN1, GRM1 | ALDH1A3 2752/4885SRC 4137/4885PTGDR2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.